Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Sipuleucel-T |
Trade Name | Provenge |
Synonyms | APC 8015 |
Drug Descriptions |
Provenge (sipuleucel-T) is composed of autologous dendritic cells exposed to a PAP-GCSF fusion protein (PA2024), which stimulates a cytotoxic immune response towards PAP-expressing tumor cells (PMID: 25565923, PMID: 25708576). Provenge (sipuleucel-T) is FDA-approved for use in patients with metastatic castration-resistant prostate cancer (FDA.gov). |
DrugClasses | |
CAS Registry Number | 917381-47-6 |
NCIT ID | C1985 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abiraterone + Sipuleucel-T | Abiraterone Sipuleucel-T | 0 | 1 |
Apalutamide + Sipuleucel-T | Apalutamide Sipuleucel-T | 0 | 1 |
Atezolizumab + Sipuleucel-T | Atezolizumab Sipuleucel-T | 0 | 1 |
Docetaxel + Sipuleucel-T | Docetaxel Sipuleucel-T | 0 | 2 |
Enzalutamide + Sipuleucel-T | Enzalutamide Sipuleucel-T | 0 | 1 |
Sipuleucel-T | Sipuleucel-T | 0 | 11 |
Sipuleucel-T + Testosterone cypionate | Sipuleucel-T Testosterone cypionate | 0 | 1 |